Health AI Central
Share:
Peer-Reviewed Publication
NPJ Metab Health Dis2026;4(1)September 1, 2026Journal Article

Higher semaglutide dose is associated with lower neuropsychiatric event incidence independent of weight loss.

Karthik Murugadoss1,2, A J Venkatakrishnan1,2, Venky Soundararajan3,4
1nference, 1 Main Street, East Arcade Building, Cambridge, Massachusetts, MA, USA.
2Metabolism Agentic Intelligence Atlas (MAIA), Cambridge, Massachusetts, MA, USA.
3nference, 1 Main Street, East Arcade Building, Cambridge, Massachusetts, MA, USA. venky@nference.net.
4Metabolism Agentic Intelligence Atlas (MAIA), Cambridge, Massachusetts, MA, USA. venky@nference.net.
PubMed DOI

Abstract

GLP1 receptor agonists (GLP-1RAs) have transformed obesity treatment, but their impact on neuropsychiatric outcomes remains poorly understood. We conducted an observational study of 63,215 patients with preexisting neuropsychiatric conditions and evaluated 24 incident neuropsychiatric outcomes following treatment initiation. In propensity-matched analyses, semaglutide was associated with broadly l…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.